Month: September 2020

Sep 15 2020

Uncategorized

Boehringer’s schizophrenia med boosts cognition in phase 2 – FierceBiotech

by Clinical Editor

No Comments

Boehringer’s schizophrenia med boosts cognition in phase 2  FierceBiotech

Sep 15 2020

Uncategorized

Pamela Turner shooting: Texas police officer indicted in death of woman with schizophrenia last year

by Clinical Editor

No Comments

A police officer has been indicted on charges of aggravated assault more than a year after fatally shooting a schizophrenic woman in Baytown, Texas, a Houston suburb. Baytown officer Juan...

Sep 15 2020

Uncategorized

Schizophrenia: Nurture cannot overcome nature

by Clinical Editor

No Comments

In the great nature vs. nurture debate, nature just got a win. UCI research led by Amal Alachkar found that too much of a certain amino acid in utero caused...

Sep 15 2020

Uncategorized

Boehringer’s schizophrenia med boosts cognition in phase 2

by Clinical Editor

No Comments

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or …

Sep 15 2020

Uncategorized

Schizophrenia Tx Eases Depression in Bipolar Disorder

by Clinical Editor

No Comments

An atypical antipsychotic approved to treat schizophrenia improved depressive episodes for patients with bipolar disorder, according to an industry-supported trial. In a group of 333 patients with …

Sep 15 2020

Uncategorized

Schizophrenia Drugs Market By Drug Class, Treatment, Application, Geography and Forecast 2020 – 2027

by Clinical Editor

No Comments

Sep 15, 2020 (Global QYResearch via COMTEX) — Acumen Research and Consulting has announced the addition of the “Schizophrenia Drugs Market” report to their offering. The report provides key …

Sep 14 2020

Uncategorized

Schizophrenia Tx Eases Depression in Bipolar Disorder

by Clinical Editor

No Comments

An atypical antipsychotic approved to treat schizophrenia improved depressive episodes for patients with bipolar disorder, according to an industry-supported trial. In a group of 333 patients with …

Sep 14 2020

Uncategorized

Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia

by Clinical Editor

No Comments

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its …

Sep 14 2020

Uncategorized

Add-On Nuplazid Gets a Win in Early Schizophrenia Trial

by Clinical Editor

No Comments

“Treatment of negative symptoms of schizophrenia remains a high unmet need as there are no currently approved treatments,” Bugarski-Kirola noted during her presentation. She explained that …

Sep 14 2020

Uncategorized

Schizophrenia: Nurture cannot overcome nature

by Clinical Editor

No Comments

In the great nature vs. nurture debate, nature just got a win. UCI research led by Amal Alachkar found that too much of a certain amino acid in utero caused...